Cargando…

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study

BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Sungpil, Choi, Hee Youn, Kim, Yo Han, Choi, SeungChan, Kim, Seokuee, Nam, Ji Yeon, Kim, Bongtae, Song, Geun Seog, Lim, Hyeong-Seok, Bae, Kyun-Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840922/ https://www.ncbi.nlm.nih.gov/pubmed/36317518 http://dx.doi.org/10.5009/gnl220050

Ejemplares similares

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
por: Kim, Hyungsub, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults
por: Wu, Lihua, et al.
Publicado: (2019)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
por: Han, Sungpil, et al.
Publicado: (2020)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers
por: Kim, Yo Han, et al.
Publicado: (2015)

Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers
por: Lee, Moon Hee, et al.
Publicado: (2023)

Amikacin/dexlansoprazole: Laryngitis: case report
Publicado: (2021)

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
por: Kim, Joon Sung, et al.
Publicado: (2023)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages
por: Han, Gong-Ho, et al.
Publicado: (2023)

Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?
por: Choi, Hyun Ho
Publicado: (2023)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
por: Wittbrodt, Eric T, et al.
Publicado: (2009)

Dexlansoprazole – a new-generation proton pump inhibitor
por: Skrzydło-Radomańska, Barbara, et al.
Publicado: (2015)

Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
por: Jeon, Hye Kyung, et al.
Publicado: (2023)

Can Nocturnal Acid-breakthrough Be Reduced by Long-acting Proton Pump Inhibitors?
por: Jeon, Hye Kyung, et al.
Publicado: (2017)

Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole
por: Wu, Justin C Y, et al.
Publicado: (2020)

Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
por: Kim, Seokuee, et al.
Publicado: (2019)

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
por: Kuo, Chia-Jung, et al.
Publicado: (2019)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021)

Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
por: Kukulka, Michael, et al.
Publicado: (2011)

Development of R packages: ‘NonCompart’ and ‘ncar’ for noncompartmental analysis (NCA)
por: Kim, Hyungsub, et al.
Publicado: (2018)

Erratum: Development of R packages: ‘NonCompart’ and ‘ncar’ for noncompartmental analysis (NCA)
por: Kim, Hyungsub, et al.
Publicado: (2018)

Caffsim: simulation of plasma caffeine concentrations implemented as an R package and Web-applications
por: Han, Sungpil, et al.
Publicado: (2017)

Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
por: Frye, Jeanetta W, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2m29v50n3krul9llusd16f7vlp